News

The deal will see MedImmune contribute both funding and a post-doctoral scientist to work within the laboratory of Professor Kevin Brindle at the University of Cambridge in the

The product is a component of the contingent rights the company received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals and its

The company is exclusively manufacturing the approved hemophilia A therapy drug Kogenate FS/Kogenate Bayer at its Berkeley facility in California. According to Bayer, establishing an additional supply source

XARTEMIS XR’s release profile combines Mallinckrodt’s newly patented technology, including design, formulation, pharmacokinetic and release characteristics, and Depomed’s advanced Acuform drug delivery technology. The drug is the first

Qudexy XR is indicated as initial monotherapy in patients ten years of age and older with POS or primary generalized tonic-clonic seizures. The once-daily, broad-spectrum antiepileptic drug is

The solution is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract. IGI

This is the first application of Intravail in a solid dosage form. The Intravail formulation is compatible with current tableting processes employed for OTC and prescription drugs and

Burman’s knew that when these drugs hit the market, they were going to require intensive management in order to reach their potential for eliminating HCV in most patients.

ChromaDex will provide GBB with quantities of its proprietary NIAGEN nicotinamide riboside (NR) ingredient. NIAGEN is the first and only commercially available form of NR, a naturally-occurring vitamin